- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02186418
Transferencia de genes para pacientes con enfermedad de células falciformes
Transferencia de genes para pacientes con enfermedad de células falciformes utilizando un vector de lentivirus de gamma globina: un estudio piloto de fase 1/2 de etiqueta abierta
The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801 (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD). Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in which all subjects completing the 2 year study visit will be asked to consent and enroll, and will followed for a further 13 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
-
Signed informed consent form.
-
Has confirmed diagnosis of sickle cell disease (SCD)
-
Has severe sickle cell disease, defined as one or more of the following:
- Minimum of two episodes of clinically diagnosed acute chest syndrome (ACS) requiring hospital admission, or one life threatening episode of ACS requiring intensive care unit (ICU) admission for exchange transfusion and/or intubation, or frequent ACS episodes which necessitate treatment with chronic transfusion therapy.
- Frequent painful vaso-occlusive episodes (VOEs) which significantly interfere with normal life activities, defined as a history of 2 or more severe acute sickle pain events per year requiring additional treatment at a medical facility outside of home pain management over the preceding 2-year period prior to study enrollment, or that necessitate chronic transfusion therapy.
- Subjects on chronic transfusion therapy for severe disease symptoms other than those listed above, and which interfere with normal life activities.
-
Has failed hydroxyurea therapy, was unable to tolerate hydroxyurea therapy, or has actively made the choice to not take the recommended daily hydroxyurea advised for severe disease (Note: must be off hydroxyurea therapy for 2 months prior to stem cell collection). If refusing hydroxyurea, the subject must document that they have been educated about the benefits and continue to refuse the treatment. Patients placed on chronic transfusion therapy instead of hydroxyurea for severe disease are eligible. Subjects unable to take hydroxyurea due to financial or safety monitoring constraints are eligible.
-
Has adequate functional status and organ function as determined at Screening.
Exclusion Criteria
- Female subjects who are pregnant or lactating/breastfeeding.
- Female subjects who are not surgically sterile, postmenopausal or who refuse to practice effective method of birth control as determined by the Investigator for one year after receiving the study drug. Women must also agree not to breastfeed for 1 year after receiving the study drug.
- Any participant of reproductive potential who refuses to agree to use an appropriate contraceptive method determined by the Investigator, for 1 year after receiving the study drug.
- Patients with an active malignant disease or receiving treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin).
- Current diagnosis or history of hepatitis B, hepatitis C, or HIV.
- Has received another study drug within 30 days, or 5 half-lives of the last dose (whichever is longer), prior to screening.
- Has severe obstruction, restriction or diffusion defect on pulmonary function tests.
- Has uncontrolled bacterial, viral or fungal infections within 1 month prior to starting the conditioning part of the study. Subjects with fever should wait for symptoms to resolve before starting the conditioning part of the study.
- Has a history of stroke or is at moderate to high risk of primary stroke (eg receiving chronic transfusions or hydroxyurea for primary prevention of stroke; has severe cerebral vasculopathy defined as moderate stenosis in >2 arterial segments; and/or has sever stenosis/occlusion in ≤2 segments in the polygon of Willis or presence of Moyamoya-like disease).
- Patients with alpha thalassemia sickle cell disease.
- Has previous liver biopsy showing cirrhosis, bridging hepatic fibrosis, or active hepatitis; or has received chronic transfusions and has previous evidence of iron overload and evidence of liver fibrosis by noninvasive liver imaging.
- Has a matched sibling donor, unless the subject has declined this option or this option is not feasible. Documentation must be included as part of the informed consent process for subjects who decline this option.
- Has a known hypersensitivity to any study treatments (e.g. melphalan, plerixafor).
Other protocol-defined inclusion-exclusion criteria may apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ARU-1801
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion. |
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Grade 3 Allergic Reaction
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion
|
Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product |
From infusion (Day 0) to 30 days post-infusion
|
|
Number of Participants Grade 4 Infection
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion
|
Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days |
From infusion (Day 0) to 30 days post-infusion
|
|
Total Number of Grade 4 Neutropenia
Periodo de tiempo: From date of chemotherapy clearance visit to to 30 days post-infusion
|
Number of participants with Grade 4 neutropenia lasting >1 month following melphalan |
From date of chemotherapy clearance visit to to 30 days post-infusion
|
|
Number of Participants With Grade 3 or 4 Toxicity Events
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion
|
Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures |
From infusion (Day 0) to 30 days post-infusion
|
|
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Periodo de tiempo: From infusion (Day 0) to 30 days post-infusion
|
From infusion (Day 0) to 30 days post-infusion
|
|
|
Number of Death Due to Study Procedures
Periodo de tiempo: From screening to the end of study, and up to 12 months.
|
From screening to the end of study, and up to 12 months.
|
|
|
Number of Hematological Malignancy
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months
|
Number of hematological malignancy due to vector insertion |
From infusion (Day 0) to end of study, up to 12 months
|
|
Number of Hematological Cancer
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months.
|
Number of hematological cancer related to investigational product or study medications/procedures |
From infusion (Day 0) to end of study, up to 12 months.
|
|
Time to Neutrophil Recovery
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months.
|
Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) < 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL) |
From infusion (Day 0) to end of study, up to 12 months.
|
|
Time to Platelet Recovery
Periodo de tiempo: From infusion (Day 0) to end of study, up to 12 months.
|
Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count < 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days > 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days) |
From infusion (Day 0) to end of study, up to 12 months.
|
|
≥8x10⁶kg Viable CD34+ Cells
Periodo de tiempo: Date of Enrollment to Infusion (day 0).
|
Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells |
Date of Enrollment to Infusion (day 0).
|
|
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced
Periodo de tiempo: Date of Enrollment to Infusion (day 0).
|
Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced |
Date of Enrollment to Infusion (day 0).
|
|
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells
Periodo de tiempo: Infusion (Day 0) to 1 year post infusion.
|
Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells |
Infusion (Day 0) to 1 year post infusion.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of HBF^G16D
Periodo de tiempo: Infusion to 12 months post-infusion
|
Percentage of HBF^G16D relative to total Hemoglobin |
Infusion to 12 months post-infusion
|
|
Change in Proportion of Antisickling/Sickling Hemoglobin
Periodo de tiempo: Enrollment to Month 24
|
Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome. |
Enrollment to Month 24
|
|
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)
Periodo de tiempo: Infusion to 12 months post-infusion
|
This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry. |
Infusion to 12 months post-infusion
|
|
Percent VCN at 6 Months
Periodo de tiempo: Infusion to 6 months post-infusion
|
This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR). |
Infusion to 6 months post-infusion
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Stella M. Davies, MB BS, PhD, MRCP, Children's Hospital Medical Center, Cincinnati
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ARU-1801_Ph1_01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .